MedTrace Logo

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

NCT05070845 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2026-05-12

No results posted yet for this study

Summary

This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This study will focus on participants with persistent (\>3 months and ≤12 months), or chronic (\>12 months) ITP

Conditions

  • Primary Immune Thrombocytopenia

Interventions

BIOLOGICAL

PF-06835375

CXCR5 inhibitor

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-02
Primary Completion
2028-08-02
Completion
2028-08-02
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Czechia
  • Hungary
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05070845 on ClinicalTrials.gov